AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the 340B program and protect 340B providers from egregious behavior by drug companies, insurers and pharmacy benefit managers.  

“Their unlawful and pernicious practices have collectively undermined the 340B program and harmed patient care,” AHA wrote. “At the same time, we have concerns regarding other aspects of this discussion draft that should be better aligned to reflect the operational realities that 340B hospitals face every day. Therefore, our comments primarily focus on how Congress can ensure that the 340B program continues to benefit patients and communities, while protecting against any unnecessary harm or burden that would jeopardize patient care.” 

Headline
The AHA Aug. 25 submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act),…
Headline
The 5th U.S. Circuit Court of Appeals Aug. 11 ruled to vacate certain regulations implementing how the No Surprises Act qualifying payment amount is calculated…
Headline
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future…
Headline
Update: The Senate passed the continuing resolution Aug. 8 by a vote of 90-6 and one present vote. The Senate is expected to vote this week on its own…
Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
The AHA July 27 expressed support for the National Nursing Workforce Center Act of 2025 (S. 1482), legislation that would establish state-based nursing…